CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Role of CAR T-Cell Therapy in Pediatric ALL Continues to Be Refined

September 14th 2018

While clinical trial findings with chimeric antigen receptor (CAR) T-cell therapy have impacted the landscape of pediatric acute lymphoblastic leukemia, additional CAR T-cell products continue to be investigated.

Dr. Locke on Bridging Chemotherapy in Patients With Non-Hodgkin Lymphoma

September 13th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of bridging chemotherapy in patients receiving chimeric antigen receptor (CAR) T-cell therapy.

CAR T Cells Continue to Be Leveraged in Lymphoma

September 12th 2018

Frederick L. Locke, MD, discusses the expansion of CAR T-cell therapy in patients with lymphomas following the 2017 approval of axicabtagene ciloleucel and remaining research questions with the therapy.

Dr. Borchmann on Next Steps With Tisagenlecleucel in DLBCL

September 10th 2018

Peter Borchmann, MD, professor, University Hospital of Cologne, Cologne, Germany, discusses next steps with tisagenlecleucel (Kymriah) in diffuse large B-cell lymphoma.

Dr. Locke on CAR T-Cell Therapy in NHL

September 10th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with non–Hodgkin lymphoma (NHL).

Dr. Locke Discusses Unanswered Questions With CAR T-Cell Therapy

September 5th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses unanswered questions with chimeric antigen receptor T-cell therapy.

Expert Discusses Latest CAR T-Cell Developments in Non-Hodgkin Lymphoma

September 5th 2018

David G. Maloney, MD, PhD, reviews the latest developments with chimeric antigen receptor T-cell therapy in patients with non-Hodgkin lymphoma.

Axicabtagene Ciloleucel Approved in Europe for DLBCL, PMBCL

August 27th 2018

The European Commission has approved axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.

Tisagenlecleucel Approved in Europe for DLBCL, ALL

August 27th 2018

The European Commission has approved tisagenlecleucel (Kymriah) for the treatment of either adult patients with relapsed/refractory diffuse large B-cell lymphoma, or patients up to 25 years of age with relapsed B-cell acute lymphoblastic leukemia.

Dr. Madduri on Eligibility for CAR T-Cell Therapy in Myeloma

August 22nd 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses eligibly criteria for patients with multiple myeloma to receive chimeric antigen receptor (CAR) T-cell therapy.

Potency of CAR T-Cell Therapy Investigated in Relapsed/Refractory MCL

August 22nd 2018

Axicabtagene ciloleucel (axi-cel; Yescarta) is being evaluated in patients with relapsed or refractory mantle cell lymphoma—a rare B-cell non-Hodgkin lymphoma that contributes 4200 new patients in the United States each year.

Dr. Lonial on CAR T-Cell Therapy in Myeloma

August 17th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma.

Tisagenlecleucel Durability Data Generate Excitement in DLBCL

August 10th 2018

Peter Borchmann MD, sheds light on the updated JULIET data and how tisagenlecleucel fits into the paradigm of diffuse large B-cell lymphoma.

Flinn Highlights CAR T-Cell Developments in Lymphoma

August 9th 2018

Ian W. Flinn, MD, PhD, discusses the latest developments with CAR T-cell therapies and other recent advances in the field of lymphoma.

Dr. Maloney on the Promise of CAR T-Cell Therapy in Hematologic Malignancies

August 3rd 2018

David G. Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the promise of CAR T-cell therapy in hematologic malignancies.

Dr. Maloney Discusses Updates With CAR T-Cell Therapy in NHL

July 18th 2018

David G. Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses updates with CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Flinn on CAR T-Cell Therapy in Non-Hodgkin Lymphoma

July 11th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

Dr. Brentjens Discusses the Future of CAR T-Cell Therapy

July 3rd 2018

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the future of chimeric antigen receptor T-cell therapy.

Axicabtagene Ciloleucel Approaches EU Approval for DLBCL, PMBCL

June 29th 2018

The European Medicines Agency’s CHMP has recommended approval of axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.

Tisagenlecleucel Nears European Approval for DLBCL, ALL

June 29th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of tisagenlecleucel for the treatment of either adult patients with diffuse large B-cell lymphoma that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse posttransplant, or in second or later relapse.